糖蛋白特异性转录反应影响埃博拉疫苗差异保护效果
本研究比较低剂量(1×10^4 PFU)VSV-Mak与VSV-Kik疫苗接种后第10天EBOV-Makona攻击的转录反应;VSV-Kik提供完全保护并快速诱导抗病毒转录变化及适应性免疫激活,VSV-Mak仅部分保护且转录反应微弱,提示糖蛋白特异性转录反应影响疫苗保护差异。
要点
- VSV-Kik低剂量接种对异源EBOV-Makona攻击提供完全保护。
- VSV-Kik快速诱导抗病毒转录变化并激活适应性免疫。
- VSV-Mak仅部分保护且转录反应微弱,提示糖蛋白特异性反应。
核心结论
- 尽管埃博拉病毒变异株高度同源,接种后转录反应仍呈现糖蛋白特异性并影响保护效果差异。
研究设计与样本
- 研究比较低剂量(1×10^4 PFU)实验级VSV-Mak与GMP级VSV-Kik接种后第10天EBOV-Makona攻击的转录反应。
主要发现
- VSV-Kik对异源EBOV-Makona攻击提供完全保护并快速诱导抗病毒转录变化及适应性免疫激活。
- VSV-Mak仅提供部分保护并诱导极小的转录反应。
关键数值与推荐
- VSV-Kik接种剂量为1×10^4 PFU,攻击时间为接种后第10天(10 DPV)。
- VSV-Kik对异源EBOV-Makona攻击提供完全保护;VSV-Mak仅部分保护。
临床怎么用
- 提示评估埃博拉疫苗时需关注糖蛋白特异性转录反应与早期保护相关性。
- 低剂量VSV-Kik可快速完全保护,有助于疫情中减轻供应负担并提高覆盖率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Since the West African Ebola virus (EBOV) epidemic in 2014-2016, recurrent outbreaks of the EBOV-Makona variant have been driven by recrudescence and human-to-human transmission emphasizing the need for effective vaccination strategies. A live-attenuated recombinant vesicular stomatitis virus (VSV)-based vaccine expressing the EBOV-Kikwit variant glycoprotein (VSV-Kik) received FDA approval in December 2019 and provides complete, rapid protection against EBOV-Makona as early as 7 days post-vaccination (DPV). During the 2018-2020 Ebola outbreak, the VSV-Kik vaccine, known as ERVEBO, was administered to lower-risk individuals at a 5-fold dose reduction of the standard 2 × 107 PFU to provide broader population protection. Identification of a protective lower dose providing rapid protection would ease supply burdens during future outbreaks and enhance vaccine coverage. We previously generated a VSV-based vaccine expressing the glycoprotein of the Makona variant (VSV-Mak) which provided complete protection against homologous challenge 28 DPV at as low as 1 × 101 PFU. However, the transcriptional responses engendered by VSV-Mak and VSV-Kik vaccines in the context of early EBOV-Makona challenge have not yet been evaluated. In the current study, we compared transcriptional responses following a low dose (1 × 104 PFU) of lab-grade VSV-Mak or GMP-grade VSV-Kik and subsequent EBOV-Makona challenge 10 DPV. VSV-Kik provided complete protection against heterologous challenge and elicited rapid antiviral transcriptional changes followed by the activation of adaptive immunity. On the other hand, VSV-Mak only provided partial protection and induced minimal transcriptional response. These results highlight a glycoprotein-specific transcriptional response after vaccination despite the high EBOV variant homology.
引用
- Wagner SB, Malherbe DC, Napier EG, et al. Glycoprotein-specific transcriptional response contributes to differential vaccine protection against lethal Ebola virus infection. Vaccine. 2026. PMID: 41819639. doi:10.1016/j.vaccine.2026.128410
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。